FDA expands pediatric indication for entrectinib and approves new pellet formulation

[FDA]

On October 20, 2023, the Food and Drug Administration granted accelerated approval to entrectinib (Rozlytrek, Genentech Inc.) for pediatric patients older than 1 month with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,


Baca selengkapnya di : http://www.fda.gov...